share_log

Mangoceuticals | 10-K: FY2023 Annual Report

Mangoceuticals | 10-K: FY2023 Annual Report

Mangoceuticals | 10-K:2023财年年报
美股SEC公告 ·  04/01 17:23

Moomoo AI 已提取核心信息

Mangoceuticals, a pharmaceutical company, has reported a series of financial and business developments in its recent announcement. Financial Performance details were not provided, hence cannot be summarized. In terms of Business Development, the company has entered into an employment agreement with Mrs. Amanda Hammer as Chief Operating Officer, effective May 1, 2023. Her compensation package includes a base salary of $150,000, a sign-on bonus comprising 75,000 shares of common stock, and options for an additional 150,000 shares. The company has also engaged in various agreements and transactions with related parties, including a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by Mangoceuticals' CEO, Jacob D. Cohen. Additionally, the company has issued stock options and shares to various executives and directors, including...Show More
Mangoceuticals, a pharmaceutical company, has reported a series of financial and business developments in its recent announcement. Financial Performance details were not provided, hence cannot be summarized. In terms of Business Development, the company has entered into an employment agreement with Mrs. Amanda Hammer as Chief Operating Officer, effective May 1, 2023. Her compensation package includes a base salary of $150,000, a sign-on bonus comprising 75,000 shares of common stock, and options for an additional 150,000 shares. The company has also engaged in various agreements and transactions with related parties, including a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by Mangoceuticals' CEO, Jacob D. Cohen. Additionally, the company has issued stock options and shares to various executives and directors, including a grant of stock options to Mr. Cohen. Future Plans were not explicitly mentioned in the announcement. The company's board has determined that several directors are independent under Nasdaq rules, and all services provided by the independent registered public accounting firm, Turner, Stone & Company, L.L.P., were pre-approved by the board for the year ended December 31, 2023.
药品公司Mangoceuticals在最新公告中报告了一系列财务和业务发展情况。由于未提供财务表现细节,因此无法总结。在业务发展方面,该公司已与首席运营官Amanda Hammer女士达成就业协议,该协议于2023年5月1日生效。她的补偿计划包括15万美元的基本工资,由普通股75000股组成的签约奖金以及另外150000股的期权。此外,该公司还与相关方达成了各种协议和交易,包括与Mangoceuticals首席执行官Jacob D. Cohen部分拥有的Epiq Scripts,LLC的主服务协议。此外,该公司还向各个高管和董事发行了股票期权和股份,包括向Cohen先生授予的股票期权。未来计划在公告中未明确提及。该公司董事会确定,根据Nasdaq规则,若干董事是独立的,并且独立注册会计师事务所Turner,Stone&Company,L.L.P.提供的所有服务都已在董事会中预先获得批准,截至2023年12月31日。
药品公司Mangoceuticals在最新公告中报告了一系列财务和业务发展情况。由于未提供财务表现细节,因此无法总结。在业务发展方面,该公司已与首席运营官Amanda Hammer女士达成就业协议,该协议于2023年5月1日生效。她的补偿计划包括15万美元的基本工资,由普通股75000股组成的签约奖金以及另外150000股的期权。此外,该公司还与相关方达成了各种协议和交易,包括与Mangoceuticals首席执行官Jacob D. Cohen部分拥有的Epiq Scripts,LLC的主服务协议。此外,该公司还向各个高管和董事发行了股票期权和股份,包括向Cohen先生授予的股票期权。未来计划在公告中未明确提及。该公司董事会确定,根据Nasdaq规则,若干董事是独立的,并且独立注册会计师事务所Turner,Stone&Company,L.L.P.提供的所有服务都已在董事会中预先获得批准,截至2023年12月31日。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息